fbpx

molecules of the month

ASTX029

oral ERK1/2 kinase and phosphorylation inhib

Ph. 1/2 candidate for solid tumors

from SBDD from prior lead

Journal of Medicinal Chemistry

Astex Pharmaceuticals, Cambridge, UK

Structure of ASTX029
1 min read

The Astex ERK1/2 kinase inhibitor, ASTX029, is an oral Ph. I-II candidate for patients with advanced solid tumors. The molecule was derived from fragment screening together with structure-based design. Interestingly, the molecule also blocks the phosphorylation/activation of ERK1/2 in addition to inhibiting its kinase activity, making it potentially more effective. Addressing CYP3A4-mediated metabolism while maintaining favorable physicochemical properties was a key aspect of lead optimization. Though metabolism studies highlighted the oxan ring as a key site of metabolism in lead molecule, the sp3-rich moiety was necessary for potency and physicochemical properties. It was found that replacement of a different region of the molecule improved stability, demonstrating that oxan metabolism is context dependent and serving as another example of a molecule having…


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: